Introduction
This review will cover the classification and clinical courses of low-grade non-Hodgkin's lymphoma (NHL), as well as types of therapies that have been evaluated for the treatment of NHL, prognostic factors used in patient evaluation, and the outcomes of clinical trials.
Classification of non-Hodgkin's lymphoma
The subtypes of NHL included in the indolent or low-grade category have, in the past, included those identified according to the National Cancer Institute Working Formulation: follicular small cleaved cell iymphoma, follicular mixed small and large cell lymphoma, and small lymphocytic lymphoma [1] . More recently described pathologic entities that do not fit precisely into the Working Formulation include mantlecell lymphoma, monocytoid B-cell lymphoma, and mucosa-associated lymphoid tissue (MALT)-type lymphoma.
Mantle cell lymphoma was originally described as diffuse intermediate lymphocytic lymphoma, and corresponds to centrocytic lymphoma according to the Kiel classification [2, 3] . With further analysis, three variants of mantle cell lymphoma have been identified: nodular, diffuse, and blastic [4] . The clinical outcomes of patients with the blastic and diffuse variants demonstrate a more aggressive clinical course, whereas patients with the nodular variant sometimes have a slightly more indolent course as described in the study by Fisher et al. [4] , which included 36 patients with mantle-cell lymphoma. The failure free and overall survival curves are shown in Figure 1 .
The variants monocytoid B-cell lymphoma and MALT lymphoma are marginal-zone lymphomas. The monocytoid B-cell lymphoma typically is a nodalbased lymphoma and has an indolent clinical course [5] . MALT lymphomas are typically extranodal with the most commonly involved primary sites being gastric, pulmonary, and bowel sites. MALT lymphomas are also considered indolent, with median survivals similar to those of follicular or monocytoid B-cell lymphomas in some series [6] .
The follicular lymphomas range from those containing mostly small cells, to a mixture of small and large cells, up to those containing mostly large cells. Depending on the histologic grading system used, various percentages of these subtypes can be obtained [7] . The clinical outcome is more favorable for those patients with a higher percentage of small cells; however, an exact prognosis based on the number of small and large cells is difficult to measure [8] . There are also patients with composite lymphomas containing a follicular pattern and a diffuse pattern within one lymph node specimen [9] , or discordant lymphomas, most commonly with a diffuse large-cell pattern in the lymph node and small cleaved cells in the bone marrow biopsy (10] . A natural progression in a fairly high percentage of follicular lymphoma patients is that of histologic transformation to a more aggressive subtype. In most studies the clinical course of patients is more aggressive once histologic transformation has occurred [11, 12] . 
Natural history of indolent lymphomas
The natural history of indolent lymphoma has been described in a group of 83 asymptomatic patients observed at Stanford University who were initially untreated [13] . Nineteen of these patients had spontaneous regression of their lymphoma without any therapy, including 30% of those with follicular small cleaved lymphoma [13] . There was no impact on survival when therapy was deferred in the patients in the Stanford study [13] . This observation was confirmed in an analysis by O'Brien et al. [14] , in a subsequent analysis at Stanford [15] , and in a randomized trial from the National Cancer Institute [16] . The actuarial survival of 1021 patients with low-grade NHL managed at Stanford by various treatment protocols or watch-and-wait strategy is shown in Figure 2 [15] . There was no difference in probability of survival in the time periods 1960 to 1975,1976 to 1986, or 1987 to 1992 . Histologic transformation to an intermediate-or high-grade lymphoma has been demonstrated in many studies involving patients with indolent lymphomas, with actual and actuarial rates ranging from 40% to 70% [12, 13, 17] . In autopsy series, the majority of patients with follicular lymphoma had evidence of histologic transformation [18] . The role that therapy for follicular lymphoma plays in the subsequent development of histologic transformation is not clear. In a study by Armitage et al. [19] , treatment of the follicular lymphoma was associated with a higher rate of transformation; however, studies from Stanford in a large number of patients did not confirm this observation ( Figure 3 ) [13] . Once histologic transformation occurs, most studies demonstrate a shortened patient survival to a median of 17 months or less, despite aggressive therapy [19] [20] [21] . However, a recent analysis by Yuen et al. [22] of the clinical course of 74 low-grade lymphoma patients with histologically transformed disease treated at Stanford demonstrated a median duration of survival after transformation of 22 months.
Evaluation of therapeutic response
The evaluation of the response to various therapies for indolent lymphomas is difficult due to a variety of issues, including the use of tests like computerized tomography (CT) scanning for evaluation of residual lymphadenopathy and the use of molecular techniques such as the polymerase chain reaction (PCR) analysis for the bcl-2 rearrangement in follicular lymphoma. Since many of the early analyses did not have the benefit of these techniques for the determination of complete remission status, the definition of complete remission has changed with time. Therefore, the comparison of complete response rates has been suggested to be an inferior method for the measurement of treatment outcomes. In addition, overall survival is difficult to use in studies of indolent lymphoma patients due to the extended survival durations of many patients. An improved method for the measurement of treatment outcome, particularly in indolent lymphomas, is the use of failure-free survival or time to treatment failure.
Therapy for low-grade lymphoma
The Ann Arbor staging system is widely used to categorize NHL and help determine treatment (Table 1) . Therapy for the various stages of low-grade NHL are described in this section.
Stage I and IIpatients
Although only 10% to 20% of parents with indolent NHL have localized disease at the time of diagnosis, a treatment program is important due to the potential for cure in a small percentage of these patients. Radiation therapy has been the mainstay of therapy for patients with localized indolent NHL. As seen in Table 2 , several studies have been published reporting the results of radiation therapy in this patient population. The 5-year disease-free survival ranges from 40% to 83% depending on the stage of disease (I vs. n), histology, and other prognostic factors such as age and disease bulk [23] [24] [25] [26] [27] . Most relapses in this patient population occur at sites outside of the radiation field and the shape of the survival curves suggest a possible plateau in the potential for a cure. It is not known if the addition of chemotherapy to adequate localized radiotherapy will improve the overall outcome of therapy for patients with localized indolent NHL.
Stage III and IVpatients
The majority of patients with low-grade NHL present with advanced disease at the time of initial diagnosis. All conventional therapies for patients with advancedstage disease at diagnosis are palliative. In this section the use of extensive radiotherapy, single-agent chemotherapy, multiagent therapy with and without an anthracycline, purine analog, dose-intensive therapy with bone marrow transplantation, and monoclonal antibody therapy will be discussed. Radiotherapy alone for patients with stage HI indolent lymphoma has been studied by a few groups. Paryani et al. [28] reported on a group of 66 patients treated with total lymphoid irradiation (TLI) and followed for up to 15 years. Favorable prognostic factors for relapse-free survival were less than five sites of involvement, absence of systemic symptoms, and tumor size less than 10 cm. In the eight patients with good prognostic factors, the relapse-free survival was 88% at 10 and 15 years [28] . However, in patients with more advanced disease and poor prognostic factors, the relapse-free survival at 10 years was about 30%. Sites of relapse in this series were typically (62% of patients with relapse) outside of the radiation ports and included epitrochlear nodes, bone marrow, or other extranodal sites; 38% of relapses were local. In another McLaughlin et al. [26] Lawrence et al. [27] No. of patients 
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Abbreviations: DLWD -diffuse lymphocytic, well differentiated; NH -nodular histiocytic; NLPD -nodular lymphocytic, poorly differentiated; NLWD -nodular lymphocytic, well differentiated; NM -nodular mixed.
• Approximate actuarial DFSs. b Described as follicular small cleaved cell NHL and follicular mixed cell, respectively. Numbers of patients not available. study by Jacobs et al. [29] , 34 patients with stage HI indolent NHL received central lymphatic irradiation between 1969 and 1985. With a median follow-up of over 9 years (range 15 to 20 years, 3 months), the actuarial overall survival was 28% at 15 years. There was one relapse observed after 9 years. The diseasefree survival was significantly improved in patients with five or fewer sites of involvement [29] .
Combined chemotherapy and irradiation regimens have also been studied in patients with advanced indolent lymphoma. However, only a few studies delineate the results of patients with stage HI vs. stage IV disease. McLaughlin et al. [30] reported their results in 74 patients with stage HI follicular lymphoma who received CHOP-Bleo (cyclophosphamide/doxorubicin/ vincristine/prednisone/bleomycin) plus involved-field irradiation. At the time of publication, the 5-year survival was 75% and the 5-year relapse-free survival was 52% for all patients [30] . Analysis of prognostic factors in this trial revealed poorer relapse-free survival in patients with a higher percentage of mixed or large cells, an elevated lactic dehydrogenase (LDH) level, and bulky disease. Only one small trial has been performed at Stanford [28] in stage HI follicular lymphoma patients, with patients randomized to receive TLI vs. TLI and CVP (cyclophosphamide/vincristine/prednisone). Among the 16 patients in this trial, there was no significant difference at 8 years (relapse-free survival 40%, overall survival 50%).
Systemic therapy
The majority of patients with indolent lymphoma have stage TV disease at the time of diagnosis. Most treatment series have reported results combining stage in and IV patients, or stage IV patients alone. Single alkylating agents such as chlorambucil or cyclophosphamide have been found to have complete response rates in advanced-stage patients ranging from 13% to 46%, with the median relapse-free survival in these trials of 12 to 35+months [31, 32] .
In a few randomized trials, single-agent alkylating therapy or combinations such as CVP have been compared with anthracycline-containing regimens such as CHOP (cyclophosphamide/doxorubicin/vincristine/ prednisone) [33] [34] [35] . In one study by Kimby et al. [33] , 259 patients with indolent lymphoma were randomized to ChP (chlorambucil/prednisone) vs. CHOP (Table 3 ). The response rate was 36% in the ChP group and 60% in the CHOP group (P < 0.01). However, the 5-year survival in the ChP group was 41% compared with 44% in the CHOP group (P = NS). In another study by Peterson et al. [34] , 45 patients with follicular mixed NHL were randomized to receive either oral cyclophosphamide or CAVPB (cyclophosphamide/doxorubicin/vincristine/prednisone/bleomycin). The estimated 5-year failure-free survival was 62% in the CAVPB group compared with 35% in the cyclophosphamide group (P -0.03).
The outcome of 415 patients with indolent lymphoma treated with a doxorubicin-based regimen by the Southwest Oncology Group (SWOG) were analyzed by Dana et al. [36] . With a median follow-up of 12.8 years, the median survival duration was 6.9 years. Multivariate analysis showed that follicular mixed histology, small lymphocytic histology, advanced age, and male sex to be among the independent predictors of a poorer survival [36] . There did not appear to be a plateau in the survival curve in any subset of patients; however, 25% of the patients with follicular mixed histology survived for prolonged periods. These results are similar to those reported for non-anthracycline-containing treatments in a similar patient population [37] . With the possible exception of patients with follicular mixed histology who were identified in the Peterson report [34] , the use of anthracycline therapy has not improved the long-term disease-free survival or overall survival of patients with indolent lymphoma The purine analogs have also been evaluated in the treatment of indolent lymphomas [38, 39] . Hochster et al. [38] treated 27 patients with indolent lymphoma with fludarabine. Twenty-five patients were assessable for response. These patients had received no more than two prior therapies and demonstrated a 20% complete response rate and a 32% partial response rate. 2-Chlorodexoyadenosine (2-Cda) has been reported to have similar efficacy to fludarabine in patients with previously treated indolent NHL. Results of various studies of the two agents are shown in Table 4 [40] . In a series of 40 patients with indolent lymphoma treated with 2-Cda, 8/40 (20%) had complete response and 9/40 (23%) had partial response [39] .
Other attempts to improve on the results of chemotherapy for the treatment of indolent lymphoma have included the addition of biologic response modifiers such as alfa-interferon, either with chemotherapy or following the conclusion of chemotherapy. Although several studies demonstrated prolongation of the disease-free interval with the addition of alfa-interferon [48, 49] , few studies have demonstrated a prolongation of survival [50] . Other biologic response modifiers, such as the monoclonal antibody anti-B4-blocked ricin, are also currently being studied posttreatment [51] .
Another therapy that appears to be quite promis- ing for indolent lymphomas includes the use of radiolabelled monoclonal antibodies such as 131 I-labelled anti-Bl administered either at low doses, such as in the study by Kaminski et al. [52] , or at higher doses with the use of autologous hematopoietic cells, as reported by Press etal. [53] .
The use of dose-intensive therapy and autologous hematopoietic stem cell transplantation for patients with indolent lymphoma has been performed at transplant centers only recently; therefore, the long-term follow-up necessary for trials involving indolent lymphoma patients has not yet occurred. In an analysis at St. Bartholomew's Hospital in London, patients receiving high-dose cyclophosphamide and total body irradiation followed by transplantation of purged autologous bone marrow for follicular lymphoma in second remission had a freedom from recurrence of approximately 50% at 5-year posttherapy. This compared to a freedom from recurrence rate of approximately 20% in historical control patients treated with conventional therapy (P < 0.001) (Figure 4 ) [54] . However, the overall survival in these two groups at the time of publication was not significantly different.
The use of dose-intensive therapy together with the use of an HLA-identical sibling donor for allogeneic transplantation has also been advocated recently for the treatment of patients with relapsed indolent lymphoma f55]. Although the acute toxicity with this therapy is greater than that of the other therapies described above, the potential for long-term disease-free survival may be superior with extended follow-up.
There are many treatment options available for patients with indolent lymphomas. The use of prognostic models such as the International Index of prognostic factors for lymphoma or other risk models may assist in identifying high-risk patients for aggressive therapies , Control (N=34) 10 12 Time (years) Figure 4 . Freedom from recurrence for patients with follicular lymphoma receiving Cy/TBI/ABMT in second remission compared with results for a historical control group. Reprinted with permission from Rohatiner, J Clin Oncol 1994,12:1181 [54] . [56, 57] . Only further clinical trials will allow for comparison of long-term outcomes in this difficult group of patients.
